# Trade Mark Journal No.2025/041 10 October 2025

## WO0000001877258 (5,44)

Office of origin: United States of America

Date of International Registration:28 August 2025
Date of designation in the UK: 28 August 2025

International priority date claimed: 4 March 2025 (United States of America) (99066169)

Class 5
  Pharmaceutical preparations and substances in the field of neurodevelopmental and neurodegenerative diseases and disorders, leukodystrophy, demyelinating diseases and disorders, and hypomyelinating diseases and disorders; pharmaceutical preparations and substances in the field of glial fibrillary acidic protein-associated diseases and disorders, alexander disease, seizures, ataxia, motor function disorders, cognitive function disorders, dysphagia, and swallowing disorders; pharmaceutical preparations and substances in the field of autosomal dominant, autosomal recessive, genetic, neurologic, parasympathetic system, neuromuscular system, skeletomuscular system, central nervous system, epileptic, pulmonary, respiratory, ophthalmic, gastrointestinal, skin, metabolic, autoimmune and lymphoproliferative diseases and disorders; pharmaceutical preparations containing zilganersen.
Class 44
  Providing health information; providing healthcare information; medical information services provided via the Internet.

Ionis Pharmaceuticals, Inc.

Representative: Paul C. Llewellyn ARNOLD & PORTER KAYE SCHOLER LLP, IP DOCKETING,, 601 Massachusetts Ave., NW, Washington DC 20001, UNITED STATES OF AMERICA